The mechanisms that regulate oxidative phosphorylation in mammalian cells are largely unknown. To address this issue, cybrids were generated by fusing osteosarcoma cells devoid of mitochondrial DNA (mtDNA) with platelets from a patient with a stop-codon mutation in cytochrome c oxidase subunit I (COX I). The molecular and biochemical characteristics of cybrids harboring varying levels of mutated mitochondrial DNA were studied. We found a direct correlation between the levels of mutated COX I DNA and mutated COX I mRNA, whereas the levels of COX I total mRNA were unchanged. COX I polypeptide synthesis and steady-state levels were inversely proportional to mutation levels. Cytochrome c oxidase subunit II was reduced proportionally to COX I, indicating impairment in complex assembly. COX enzymatic activity was inversely proportional to the levels of mutated mtDNA. However, both cell respiration and ATP synthesis were preserved in cells with lower proportions of mutated genomes, with a threshold at ϳ40%, and decreased linearly with increasing mutated mtDNA. These results indicate that COX levels in mutated cells were not regulated at the transcriptional, translational, and post-translational levels. Because of a small excess of COX capacity, the levels of expression of COX subunits exerted a relatively tight control on oxidative phosphorylation.
The mechanisms that regulate oxidative phosphorylation in mammalian cells are largely unknown. To address this issue, cybrids were generated by fusing osteosarcoma cells devoid of mitochondrial DNA (mtDNA) with platelets from a patient with a stop-codon mutation in cytochrome c oxidase subunit I (COX I). The molecular and biochemical characteristics of cybrids harboring varying levels of mutated mitochondrial DNA were studied. We found a direct correlation between the levels of mutated COX I DNA and mutated COX I mRNA, whereas the levels of COX I total mRNA were unchanged. COX I polypeptide synthesis and steady-state levels were inversely proportional to mutation levels. Cytochrome c oxidase subunit II was reduced proportionally to COX I, indicating impairment in complex assembly. COX enzymatic activity was inversely proportional to the levels of mutated mtDNA. However, both cell respiration and ATP synthesis were preserved in cells with lower proportions of mutated genomes, with a threshold at ϳ40%, and decreased linearly with increasing mutated mtDNA. These results indicate that COX levels in mutated cells were not regulated at the transcriptional, translational, and post-translational levels. Because of a small excess of COX capacity, the levels of expression of COX subunits exerted a relatively tight control on oxidative phosphorylation.
Cytochrome c oxidase (COX) 1 is the terminal component of the mitochondrial respiratory chain. It transfers electrons from reduced cytochrome c to molecular oxygen and contributes to generating the electrochemical gradient across the inner mitochondrial membrane. The mammalian COX is an enzymatic complex of the inner mitochondrial membrane composed of 13 subunits (1), three of which (I, II, and III) are encoded by the mitochondrial DNA (mtDNA), whereas the other 10 are encoded by nuclear DNA. Subunit I and II form the catalytic center of the enzyme (2, 3) . The other subunits play structural and regulatory roles and are involved in the dimerization of the enzyme and in the formation of oxygen channels (4) .
COX deficiency is a common biochemical finding associated with mitochondrial disorders. Isolated COX deficiencies have been reported in a number of mendelian disorders due to nuclear genes; mutations in SURF-1 affect COX assembly (5, 6) , mutations in SCO1 (7) and SCO2 (8) affect copper metabolism and insertion in the apoenzyme, and mutations in COX10 affect biosynthesis of heme (9) . So far, no mutations in nuclear genes encoding for COX subunits have been associated with human diseases. Usually, in mitochondrial disorders caused by large scale deletions of mtDNA and by mutations in the mitochondrial tRNA genes, there is a deficit of multiple respiratory chain enzymes including COX (10) . However, isolated COX deficiencies due to mutations in the mtDNA genes coding COX subunits have been identified in rare, usually sporadic, patients (6, (11) (12) (13) (14) .
The peculiar characteristics of mammalian mitochondrial genetics, where each cell contains a large number of mtDNAs in the order of 10 3 -10 5 copies (15) render the issues of "gene dosage" and "threshold" for phenotypic effect very compelling, especially in the case of mtDNA mutations. In fact, very little is known about the regulation of the expression of genes involved in OXPHOS in mammalian mitochondria in response to mtDNA abnormalities. In most cases, mtDNA harboring pathogenic mutations coexist with wild-type mtDNA, a condition called "heteroplasmy." It is well known that for many tRNA point mutations a relatively high proportion of mutated mtDNAs is required to determine OXPHOS defects (10) . This is probably because of the ability of the remaining normal tRNAs to complement the function of the defective ones, suggesting that tRNAs are normally synthesized in excess of the minimum required for normal mitochondrial protein synthesis (16, 17) . On the contrary, despite the apparent genetic redundancy, mutations in mtDNA genes encoding COX subunits seem to cause enzymatic defects at low levels of heteroplasmy (i.e. low proportions of mutated mtDNA). Ostensibly, the level of heteroplasmy corresponding to the threshold for COX deficiency in the muscle of patients harboring mutations in COX genes is ϳ40%, as demonstrated by genetic and biochemical analyses of COX deficient fibers (11, 12, 14) .
Studies performed on intact human cultured cells treated * This work was supported by grants from the National Institute of Health (to G. M.), New York Academy of Medicine, Speakers Fund (to G. M.), the Muscular Dystrophy Association (to G. M., F. P., and A. B.), and Telethon, Italia (to C. B,). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
* with increasing doses of the COX inhibitor KCN demonstrate that COX capacity is in low excess compared with that required to support normal cell respiration (18, 19) . Therefore, COX appears to operate a tight regulation on cell respiration in mammalian cells. To better understand how genetic defects in mtDNA-coded COX subunits affect the regulation of OXPHOS in vivo, we have analyzed a set of transmitochondrial cell lines (cybrids) containing various proportions (from 0 to 100%) of a G6930A stop-codon mutation in the COX I gene (13) .
EXPERIMENTAL PROCEDURES
Cell Culture-Cybrids were generated by fusion of platelets from a patient with the G6930A mtDNA mutation with human osteosarcoma 143B cells lacking mtDNA ( 0 cells) as described elsewhere (13) . Ethidium bromide was used to manipulate the mtDNA content in a cell line with 65% of mtDNA mutation (20) . Exponentially growing cells were cultured in DMEM supplemented with 5% fetal bovine serum, 50 ng/ml ethidium bromide, and 50 g/ml uridine for 9 or 11 days. After ethidium bromide treatment cells were replated in 100-mm tissue culture dishes at the cloning dilution of 100 cells/plate. Subclones were isolated with cloning rings and expanded for genetic, molecular, and biochemical analyses.
Growth of subclones in selective conditions were determined by seeding 35-mm plastic Petri dishes with 5 ϫ 10 4 cells in 3 ml of Dulbecco's modified Eagle's medium without glucose supplemented with 5% dialyzed fetal bovine serum, 110 mg/liter sodium pyruvate, 5 mM galactose, 50 g/ml uridine. Cell counts were obtained daily for 6 days.
Mutation Analysis-Total DNA was extracted from exponentially growing cells by standard techniques. PCR/RFLP analysis was performed to detect the G6930A mutation and to quantify the proportion of mutated mtDNA as described elsewhere (13) . Radiolabeled mtDNA fragments digested with AluI were separated on a 12% polyacrylamide gel and quantified with Cyclone phosphorimager using the OpiQuant software (Hewlett Packard).
RNA Analyses-Total RNA was extracted from a semi-confluent 100-mm dish (ϳ10 7 cells) using a ToTALLY ® RNA kit (Ambion) following the manufacturer's protocol. RNA yield was measured by UV absorbance.
For Northern blot analyses, 16 g of total RNA were loaded on a 1.5% agarose-formaldehyde gel following the described protocols (21) . RNA was blotted on a Zeta-Probe membrane (Bio-Rad) according to the manufacturer's recommendations. The membrane was probed sequentially with mtDNA fragments corresponding to portions of COX I (nucleotides 6459 -7315) and ND2 (nucleotides 4485-5420) genes, and ␤-actin DNA (CLONTECH) were labeled with [ 32 P]dATP by a random primer labeling kit (Roche Molecular Biochemicals). Intensities of RNA bands were quantified with Cyclone phosphorimager using the OpiQuant software (Hewlett Packard).
For RT-PCR/RFLP analyses of mt-cDNA, 5-8 g of total RNA were subjected to DNase I digestion for 1 h at 37°C. The reaction was arrested by incubation at 75°C for 15 min. One g of DNase I-digested RNA was used for cDNA synthesis using a Thermoscript RT-PCR system (Life Technologies, Inc.) following the manufacturer's protocol. Total cDNA was incubated with RNase A to digest any residual mtRNA) for 1 h at 37°C. PCR amplification of COX I cDNA fragments encompassing the G6930A mutation was performed as described elsewhere (13) . To exclude potential mtDNA contamination and unprocessed mtRNA, another PCR reaction was carried out using the primers 11F (3Ј position at mtDNA nucleotide 7148 in the COX I gene) and 11R (3Ј position at mtDNA nucleotide 8095 in the COX II gene). These primers could only amplify mtDNA and unprocessed mtRNA. PCR products were radiolabeled, digested with AluI, and quantified as described above.
Respiratory Chain Analyses-For oxygen consumption measurement, cells were fluid-changed with fresh medium 1 h before performing the assays. Cells were collected by trypsinization, pelleted by centrifugation, counted, and resuspended at 5 ϫ 10 6 cells/ml in Dulbecco's modified Eagle's medium lacking glucose and containing 110 mg/ml pyruvate at 37°C. 0.3 ml of cell suspension was transferred into an oxygraph chamber equipped with a Clark-type electrode (Hansatech). After adequate time for accurate slope measurement, the coupled endogenous respiration was inhibited by 1.5 mM KCN. A replicate measurement on the same cell suspension was carried out in the presence of 3 M FCCP.
For respiratory chain activity assays, the mitochondrial fraction was isolated from two semiconfluent cultures on 150-mm dishes as described elsewhere (22) . Complex I ϩ III, complex IV, and citrate synthase activities were measured as described elsewhere (23) .
ATP Synthesis Assays-For ATP synthesis measurements (24) , cells were fluid-changed with fresh medium 1 h before performing the assay. Cells were collected by trypsinization, pelleted by centrifugation, counted, and resuspended at 1 ϫ 10 7 cells/ml in buffer A containing 150 mM KCl, 25 mM Tris-HCl, 2 mM EDTA, 0.1% bovine serum albumin, 10 mM potassium phosphate, 0.1 mM MgCl 2 , pH 7.4. 160 l of the cell suspension was incubated with 50 g/ml digitonin for 1 min at room temperature, diluted with 1 ml of buffer A, and centrifuged at low speed for 1 min. The cell pellet was resuspended in 160 l of buffer A, and 0.15 mM Ap 5 A, 0.1 mM ADP, 1 mM malate, 1 mM pyruvate, and 10 l of buffer B containing 0.8 mM luciferin and 20 g/ml luciferase were added. The light emission was recorded by an Optocomp I luminometer (MGM Electronics) at 15-s intervals for a total recording time of 4 min. Each measurement was replicated with the addition of 1 g/ml oligomycin to determine the non-mitochondrial ATP synthesis. A standard ATP/luminescence curve was constructed by measuring luminescence of different ATP concentrations.
Analyses of Mitochondrial Translation Products-To measure the rate of mitochondrial protein synthesis, pulse-labeling experiments with [
35 S]methionine were performed according to the method of Chomyn et al. (25) . Samples of 2 ϫ 10 6 cells were plated on 100-mm Petri dishes, incubated overnight, washed with methionine-free Dulbecco's modified Eagle's medium, and then incubated for 7 min at 37°C in 4 ml of the same medium containing 50 g/ml cytoplasmic translation inhibitor emetine. Thereafter, [
35 S]methionine (0.2 mCi (1.75 Ci/ mmol)/plate) was added, and the cells were incubated for 20 min. Cells were trypsinized, washed in phosphate-buffered saline, and lysed in 1% SDS. 40 g of protein were electrophoresed through an SDS, 15% polyacrylamide gel. The intensities of the bands corresponding to mitochondrial translation products were quantified with Cyclone phosphorimager using the OpiQuant software (Hewlett Packard). Immunoblot analyses of equal amounts of total cell proteins (30 g) was performed as described elsewhere (26) using mouse monoclonal antibodies against COX I and COX II (Molecular Probes).
For separation of mitochondrial complexes under native conditions, cells from exponentially growing cultures were collected by trypsinization, resuspended in phosphate-buffered saline, and counted. Crude mitochondrial pellets were obtained by incubating 1 ϫ 10 6 cells in 200 l of phosphate-buffered saline for 10 min on ice with 4 mg/ml digitonin, pelleted by centrifugation at 12,000 ϫ g, and washed with phosphatebuffered saline (27) . Pellets were resuspended in 100 l of 1.5 M 6-aminohexanoic acid, 50 mM bis-Tris, pH 7.0. Membrane complexes were extracted by adding 10 l of 10% n-dodecyl maltoside and incubating cells on ice for 15 min. After centrifugation, the supernatant was mixed with 10 l of 5% Serva Blue G in 1 M 6-aminohexanoic acid and loaded on a 5-10% gradient gel. (28) . COX was immnunodetected by Western blot using mouse monoclonal antibodies against COX I (Molecular Probes).
RESULTS

Isolation and Genetic Characterization of Cybrid Cell
Lines-To obtain cybrid cell lines containing various different proportions of mtDNA G6930A point mutation, a previously characterized heteroplasmic cybrid clone with ϳ65% mutated mtDNAs (13) was subjected to ethidium bromide treatment for 9 or 11 days. By decreasing the mtDNA copy number, ethidium bromide increases the likelihood of skewed mitotic segregation of the mtDNAs in dividing cells. After ethidium bromide treatment, cells were plated at low concentrations in medium containing uridine. mtDNA from single-cell-derived subclones was analyzed by PCR/RFLP. As expected, these subclones contained various amounts of mutated mtDNA ranging from 0 to 100% (Fig. 1A) . A genetic drift of mtDNA resulting in a variation of the proportion of mutated mtDNA over time has been described in heteroplasmic cell lines (29, 30) . The content of mutated mtDNA was measured periodically in a subset of our subclones for 90 days of continuous culture. We found that some heteroplasmic subclones had a tendency to drift toward higher levels of mutated mtDNA, although they always maintained their heteroplasmic state (Fig. 1B) . There was no apparent correlation between the initial proportion of mutated mtDNA and its tendency to shift upward or remain stable. For this reason, a portion of the cells was set aside and utilized for DNA extraction each time an experiment was performed to determine the exact proportion of mutated genomes at that particular time point.
COX I mRNA-To investigate whether the G6930A stopcodon mutation had any effect on COX I gene transcription, total RNA was extracted, and total cDNA was generated by RT. Samples were treated with DNase prior to RT to eliminate any residual mtDNA. To ensure that all residual mtDNA had been eliminated, cDNAs were subjected to PCR amplification with a forward primer corresponding to COX I gene and a reverse primer complementary to COX II gene. As expected, no PCR products were generated from the cDNA samples, whereas the positive mtDNA controls generated the 948-bp target product (not shown). cDNAs were subjected to PCR-RFLP to determine the relative content of mutated mtRNA ( Fig. 2A) . RNA from parental 143B 0 cells was used as a negative control and did not yield any PCR product (not shown) excluding the presence of COX I-expressed nuclear pseudo-genes. There was a linear correlation between the proportion of mutated mtDNA and mutated mRNA (Fig. 2B) , indicating that in heteroplasmic cells the rate of transcription of wild-type and mutated COX I genes was the same. We also looked at total COX I mRNA levels by Northern blot analysis (Fig. 2C) . The COX I mRNA normalized to ␤-actin mRNA varied in different cell lines from 2.75 to 4.70 (Fig. 2D) . However, there was no correlation between the proportion of mutated mtDNA and relative COX I mRNA content. Quantification of ND2 mRNA, another mtDNA-encoded gene unrelated to the G6930A mutation, also showed variability among subclones with no correlation with the proportion of mutated genomes (Figs. 2, C-D) . These results show that the stop-codon mutation had no qualitative or quantitative effects on COX I mRNA expression and presumably did not affect the transcription of other mtDNA genes.
COX I Protein Synthesis and Steady-state Levels-Mitochondrial translation products were labeled for 20 min with [ 35 S]methionine in the presence of the cytosolic protein translation inhibitor emetine (Fig. 3A) . Although equal amounts of proteins were loaded in each lane to correct for potential differences in protein loading, the intensity of the band corresponding to COX I was normalized to that of the ATPase subunit 6 (A6), and the amount of COX I polypeptide synthesized was expressed as the ratio COX I:A6. Although there was a gap between clones containing 8 and 58% mutated mtDNA, the trend of the data suggested a linear correlation between the proportion of mutated mtDNA and the decrease in synthesized COX I polypeptide (Fig. 3B) .
Protein steady-state levels were assayed by Western blot using monoclonal antibodies against COX I and COX II (Fig.  4A) . The intensities of the bands corresponding to the two COX subunits were quantified by densitometry. Again, we observed a direct correlation between the decrease in COX I steady state levels and the proportion of mutated mtDNA. Interestingly also, COX II was decreased in parallel with COX I (Fig. 4B) . Because COX II synthesis was normal in mutated cells, the reduction in COX II steady-state levels was due to protein degradation, presumably caused by lack of complex IV assembly.
COX assembly was assayed in blue-native gel electrophoresis. As expected, the loss of COX I caused a deficit of COX assembly. Although we expected in cells with 65% mutated mtDNAs, assembled COX should have been 35% normal, using anti-COX I antibodies we found that as little as 65% mutated genomes caused complete disappearance of immunoreactive assembled COX IV (Fig. 4C) . However, it has been shown that only ϳ80% of COX can be extracted under the mild conditions used (31). Moreover, it is possible, that the sample preparation for native gels did not allow for complete antigen presentation for the anti-COX I antibody, leading to an underestimation of assembled complex IV. In agreement with the results obtained by Western blot, immunostaining of the native blot with antibodies to anti-COX II also showed the absence of reactive material in cells with 65% mutated genomes (not shown). The apparently inverse linear correlation between the proportion of mutated mtDNA and the decrease in COX I protein suggested that the remaining wild-type mtRNAs were not able to compensate for the lack in COX I protein translation caused by the mutation. Moreover, COX I protein turnover and degradation were unchanged in mutated cells, again suggesting that any compensatory mechanisms at the protein level was either very small or not present at all.
Respiratory Chain Activities-COX activity measured in mitochondrial fractions was decreased proportionally to the mutation load (Fig. 5A ). This correlation was maintained when COX activities were normalized by the activity of citrate synthase (Fig. 5B) , a nuclear-encoded matrix enzyme of the Krebs cycle, to correct for the possible variations in mitochondrial content due to the isolation procedures. In addition, the activity of complex I ϩ III (NADH-cytochrome c oxidoreductase) was unchanged in mutated cells (Fig. 5C ). These results showed that there was no threshold for COX enzymatic activity and that there was no compensatory increase of the other mitochondrial enzymes that would have resulted in a steeper decrease of the COX:citrate synthase ratio and higher complex I ϩ III activities in mutated cells.
Cell Respiration and ATP Synthesis-Oxygen consumption was assayed in intact cells respiring in Dulbecco's modified Eagle's medium containing pyruvate and L-glutamine as the sole energy sources. Cell respiration was almost completely inhibited by the addition of 1.5 mM KCN, a specific inhibitor of complex IV. Cell respiration plotted against the proportion of mutated genomes showed almost normal rates up to ϳ30 -40%, above which there was a steep decrease linearly correlated with the mutation load (Fig. 6A) . To avoid the potential influence of proton cycling and OXPHOS on cell respiration, cells were completely uncoupled with 3 M FCCP, a potent protonophore. The addition of FCCP increased the cellular respiration rate by ϳ100%. However, the correlation between respiration and mutation load did not change. Cells harboring 30 -40% mutated genomes were still able to sustain almost normal cell respiration with a steep drop at higher levels of mutation (Fig. 6B) .
ATP synthesis was measured by luminometry in permeabilized cells using malate and pyruvate as substrates with and without the addition of 15 g/ml of the ATPase inhibitor oligomycin. In wild-type cells, more than 90% ATP synthesis was oligomycin-sensitive, indicating its mitochondrial origin. As for cell respiration, mitochondrial ATP synthesis plotted against the proportion of mutated genomes was normal up to 30 -40%, above which there was a sharp decrease that correlated linearly with the mutation load (Fig. 6C) .
Cell Growth in Galactose Medium-We investigated the impact of reduced respiratory chain functions on cell survival in culture conditions where ATP synthesis depends primarily on oxidative metabolism. Cells were grown in medium lacking glucose and containing pyruvate and galactose. Galactose can enter glycolysis via three consecutive reactions that convert galactose to glucose 6-phosphate. Because in cultured cells this reaction is much slower than the conversion of glucose to glucose 6-phosphate by hexokinase, the ATP produced by galactose-derived glycolysis alone is not sufficient for cell viability. Therefore, cells have to rely on mitochondrial OXPHOS as the main source of ATP (32) . There was a rather high degree of variability in growth rates among clones also in medium containing glucose that was unrelated to the proportion of mutated genomes. However, in medium containing galactose and pyruvate the growth of cells harboring more than 50% mutated genomes was dramatically decreased, and cells containing more than 70% mutated genomes were unable to divide after only 2 days of culture (data not shown). Therefore, we estimated that the threshold of mutated genomes for defective growth in oxidative conditions was ϳ50%.
DISCUSSION
In the present work, the metabolic effects of a stop-codon mutation in the mitochondrial gene coding for COX I were studied in cultured human cells. The G6930A mtDNA mutation creates a stop-codon resulting in a predicted loss of 170 amino acids, approximately 1/3 of the polypeptide. A mitochondrial translation product corresponding to truncated COX I was not detected by gel electrophoresis of radiolabeled newly synthesized peptides or by immunoblotting even in cells containing 100% mutated genomes. This suggested that the loss of the C-terminal portion presumably prevented insertion in the inner mitochondrial membrane and assembly with the other components of COX, leading to rapid degradation of the truncated protein (13) . For this reason, we speculated that a dominant negative effect of the mutation due to misincorporation of an inactive truncated peptide in COX holoenzyme was unlikely. To assess how cells respond to increasing levels of COX deficiency, we analyzed the molecular and biochemical characteristics in a series of subclones obtained by prolonged treatment with ethidium bromide of a heteroplasmic cybrid cell line that contained varying proportions of mutated genomes.
Correlation between mtDNA Mutation, COX I mRNA, Protein Synthesis, and Enzyme Activity-The direct correlation between levels of COX I-mutated mtDNA and mutated mRNA observed in our cellular model strongly suggested the absolute lack of compensatory up-regulation and stabilization of wildtype mRNA as compared with mutated mRNA. Our results are in line with those obtained by Bai et al. (33) in mouse cybrids harboring a nonsense mutation in the mitochondrial gene encoding for subunit 5 of complex I (ND 5). Moreover, we found no change in total COX I mRNA levels in mutated cells, again suggesting a lack of compensatory up-regulation of transcription, of mRNA stabilization, and of selective degradation of mutated mRNAs. Bai et al. (33) came to similar conclusions in the ND5-mutated cells, although in their model there was a decrease of total ND5 mRNA content in cybrid subclones containing almost homoplasmic levels of mutated mtDNA (33) . Albeit total mRNA levels were rather variable among subclones, we did not find any evidence of a trend toward decreasing COX I mRNA levels in cells containing very high proportions of mutated mtDNA. We could not exclude the existence of a threshold for protein synthesis defect because our protein synthesis analyses lacked data points between 8 and 58% mutated mtDNA. However, an inverse linear correlation between the proportion of mutated mtDNA and the levels of COX I polypeptide was supported by the observation that COX activity decreased linearly with increasing mtDNA mutation, even at relatively low levels of mutated genomes (i.e. 28%). Because the stop-codon mutation most likely caused COX deficiency by decreasing the levels of COX I polypeptide, any compensatory effect at the protein level was presumably either very small or absent.
On the other hand, Bai et al. (33) report that in ND5-mutated cells the proportion of mutated mtDNA above which ND5 protein levels and complex I activity were decreased was ϳ40%. The reason for this difference could partially depend on the turnover rate of the polypeptide affected by the mutation, and at this point, we don't know if COX I and ND5 turnover rates in mammalian cells are different. It should also be taken into account that the ND5 mutation was studied in mouse lung carcinoma cells, whereas our COX I mutation was studied in human osteosarcoma cells. Again, we don't know if differences exist between mitochondrial peptide turnover rates in different cell types and in different mammalian species. Alternatively, there could be an effect of mitochondrial translation factors that modulate the synthesis of polypeptides, since this has been observed in isolated rat brain synaptosomes, where the synthesis of ND5 was differently regulated than that of other mitochondrial polypeptides (34) . In any case, both our observations and those of Bai et al. (33) agree in demonstrating that in the case of protein-coding gene mutations the threshold for protein synthesis defects is either low or absent. On the contrary, mutations of the tRNA gene, which are expressed severalfold more than the minimum required for normal protein synthesis, have very high thresholds (16, 17) . It will be important to identify and analyze cellular models with mtDNA nonsense or frameshift mutations in different genes to determine whether the threshold values found in COX I and in ND5 mutants can be extended to other mitochondrial protein-coding genes.
Complex IV Stability-It has been proposed that in mammalian cells complex IV is assembled in a process that entails several steps and proceeds through the formation of different intermediates. COX I together with subunit IV seems to be part of the first intermediate complex that is formed (27) , suggesting that COX I has a primary role in the assembly of complex IV. It has been previously reported that cells partially depleted of COX I also lack COX II (13) . Accordingly, we have found a profound reduction of fully assembled complex IV in cells containing high levels of COX I-mutated mtDNA (i.e. Ͼ65%). We have also shown that the steady-state levels of another mtDNA-coded complex IV subunit, COX II, were reduced proportionally to those of COX I despite being normally synthesized. Similarly, a lack of COX II has been reported in the muscle of a patient with a frameshift micro-deletion in COX I (35) . Moreover, Tiranti et al. (6) demonstrate that in cells harboring a COX III frameshift mutation, there was a reduction of COX I and COX II steady-state levels even though they were normally synthesized (6) . Also, in cells harboring virtually homoplasmic levels of a 15-bp deletion in COX III, there was a decrease of COX I and COX II steady-state levels (36) . These observations strongly support the concept that in mammalian cells, COX subunits that are not properly assembled due to a lack of assembly intermediates are rapidly degraded. Also, in mutants of the yeast Saccharomyces cerevisiae lacking individual COX subunits there is a reduction in the steady-state levels of the other constituents of the complex, particularly those encoded by mtDNA (37) . Those polypeptides are lost as a result of proteolysis, and it seems that only the fully assembled complexes are protected against the action of endogenous proteases (37) . Therefore, mitochondrial polypeptide steady-state levels in vivo appear to depend more on their turnover rate than on transcriptional or translational regulation.
COX Threshold and Maximum COX Capacity for Cell Respiration and ATP Synthesis-We correlated residual COX activity with cell respiration and ATP synthesis rates in cybrid subclones containing varying proportions of mutated mtDNA. Percentages of residual respiration and ATP synthesis plotted against the percentage of COX deficiency were unchanged up to a threshold point, where they started decreasing in a linear correlation with increasing COX deficiency (Figs. 7, A-C) . Substituting the value 100 (corresponding to 100% respiration or ATP synthesis) to the y value in the equation that defines the best-fit linear regression lines in each plot (Figs. 7, A-C) , we derived the x values corresponding to the COX deficiency threshold points. The estimated threshold values were 37% for coupled cell respiration, 44% for uncoupled cell respiration, and 46% for ATP synthesis. Similarly, in cells with more than 50% mutated genomes, we found markedly decreased growth rates in galactose-containing medium, which requires oxidative metabolism to maintain adequate ATP synthesis. Interestingly, also Porteous et al. (38) have shown that in a set of cybrids containing various levels of the mtDNA 4997-bp "common" deletion, the threshold for ATP synthesis defect was around 50% deleted genomes.
From the plots in Fig. 7 , we have determined the theoretical maximum COX capacity corresponding to the intersection of the best-fit linear regression lines with the y axis, expressed as a ratio to the actual values obtained in cells with 0% COX deficiency. The maximum COX capacity values were 1.5 for coupled respiration, 1.7 for uncoupled respiration, and 1.9 for ATP synthesis.
The equations for endogenous respiration and ATP synthesis rates conformed to the general equation proposed for endogenous respiration by Villani and Attardi (18) , COX Ri ϭ COX Rmax (100 Ϫ x), where x represents the percent inhibition of COX activity at i concentration of the inhibitor KCN, COX Ri represents the percentage of endogenous respiration rate at i concentration of the inhibitor KCN, and COX Rmax represents the ratio of the maximum COX capacity to the maximum endogenous respiration rate. In their experiments, Villani and Attardi (18) used, among other lines, osteosarcoma 143B cells, the same parental cells from which our cybrids were derived, treated with different concentrations of the COX inhibitor KCN. They found a 28% threshold for endogenous respiration and a maximum COX capacity 1.4 times higher than the endogenous respiration rate. The difference in the threshold values of COX deficiency observed by us and Villani and Attardi (18) in uncoupled endogenous respiration (44 and 28%, respectively) could be attributed to several factors. First, instead of a single cell line, we looked at a number of cybrid subclones that might have differed slightly in their metabolic regulation. Second, the KCN inhibition system used by Villani and Attardi (18, 19) might not exactly compare biochemically to our genetic model of COX deficiency. Last, these authors measured both COX activity and endogenous respiration in whole cells by polarographic methods, whereas we measured COX activity on mitochondrial fractions by spectrophotometry and cell respiration by polarography. However, both Villani and Attardi (18) and our results show that the reserve of COX capacity in living cells is limited, and the threshold for respiratory and ATP synthesis defects could be reached at values of residual COX activity of ϳ60 -70%. This could have important implications in the relationship between mtDNA mutation in COX genes and their consequences on OXPHOS functions in patients with mitochondrial disorders. Although it is not known how OX-PHOS regulation differs in human tissues from cultured cells, the excess COX capacity was also estimated to be ϳ1.4 in isolated permeabilized muscle fibers (39) . These data are consistent with the finding that the threshold for COX deficiency in the muscle of patients harboring mutations in COX genes is usually around 40%, as estimated by single fiber PCR/RFLP analyses of COX-deficient fibers (12, 14, 40) . Thus, it is likely that a mild (i.e. less than 30%) COX deficiency will not cause impairment of respiration and ATP synthesis in muscle fibers. Although there might be differences in the way OXPHOS is regulated in different tissues in vivo, this caveat should be considered when assessing the physiological significance of low levels of mtDNA mutations and mitochondrial enzyme defects found in patients affected by chronic degenerative disorders such as Alzheimer's and Parkinson's diseases.
